Surgery Partners Inc. Common Stock (SGRY)
Stock · NASDAQ · Health Care
$14.61as of 10/16/2026
Price chart
Active signals
SGRY Signal Track Record
How signals performed across all stocks →What SGRY's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 36 | -2.6% | 44% | September 17, 2026 |
| Bollinger Band Breakdown | 23 | +3.5% | 61% | September 17, 2026 |
| Bollinger Band Breakout | 22 | -2.9% | 41% | September 22, 2026 |
| 200-Day Moving Average TouchActive now | 15 | -6.0% | 13% | September 23, 2026 |
| Any 20-session window (baseline) | -2.4% | 42% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About SGRY
Surgery Partners, Inc., together with its subsidiaries, owns and operates a network of surgical facilities and ancillary services in the United States. The company provides ambulatory surgery centers and surgical hospitals that offer non-emergency surgical procedures in various specialties, including orthopedics and pain management, ophthalmology, gastroenterology, and general surgery. It offers emergency departments…
- Sector
- Health Care
- Industry
- Hospital/Nursing Management
- Employees
- 16,000
- Website
- surgerypartners.com/
Fundamentals
- 1-day range
- $14.51$14.89
- Market cap
- $1.95B
- P/E (trailing)
- —
- P/E (forward)
- 52.18
- EPS (trailing)
- $-0.71
- Dividend yield
- —
- Beta
- 2.00
- Avg. volume
- 2.16M
How Surgery Partners Inc. Common Stock Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Mar 2, 2026 · via SEC EDGAR / Finnhub
Forecasts
11 analyst ratings
Surgery Partners Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- SGRYSurgery Partners Inc. Common Stock$14.61▼ 1.08%Market cap $1.95BP/E —$11.41$23.44
- SNDASonida Senior Living Inc. Common Stock$35.29▼ 1.62%Market cap $1.91BP/E —$24.95$44.39
- MDPediatrix Medical Group Inc. Common Stock$27.38▼ 1.37%Market cap $2.15BP/E 12.55$15.82$27.94
- ARDTArdent Health Inc. Common Stock$11.95▼ 2.05%Market cap $1.66BP/E 21.49$7.71$15.48
- HCSGHealthcare Services Group Inc. Common Stock$21.13▼ 1.40%Market cap $1.51BP/E 11.90$15.5$25.75
- NHCNational HealthCare Corporation Common Stock$242.82▼ 1.10%Market cap $3.43BP/E 26.97$117.22$239.29
- BKDBrookdale Senior Living Inc. Common Stock$10.09▲ 0.00%Market cap $3.43BP/E —$8.02$17.09
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| SGRY Surgery Partners Inc. Common Stock | $1.95B | — | $14.61 | ▼ 1.08% | $11.41$23.44 |
| SNDA Sonida Senior Living Inc. Common Stock | $1.91B | — | $35.29 | ▼ 1.62% | $24.95$44.39 |
| MD Pediatrix Medical Group Inc. Common Stock | $2.15B | 12.55 | $27.38 | ▼ 1.37% | $15.82$27.94 |
| ARDT Ardent Health Inc. Common Stock | $1.66B | 21.49 | $11.95 | ▼ 2.05% | $7.71$15.48 |
| HCSG Healthcare Services Group Inc. Common Stock | $1.51B | 11.90 | $21.13 | ▼ 1.40% | $15.5$25.75 |
| NHC National HealthCare Corporation Common Stock | $3.43B | 26.97 | $242.82 | ▼ 1.10% | $117.22$239.29 |
| BKD Brookdale Senior Living Inc. Common Stock | $3.43B | — | $10.09 | ▲ 0.00% | $8.02$17.09 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Surgery Partners (SGRY) Faces Softer Volumes With Fair Value Still HigherYahoo · 10/10/2026
- Is Surgery Partners (SGRY) Cheap After a 65% Five Year Fall?Yahoo · 10/9/2026
- 1 Russell 2000 Stock with Competitive Advantages and 2 Facing HeadwindsYahoo · 10/9/2026
- RBC Capital Reiterates Outperform on Surgery Partners, Maintains $19 Price Targetbenzinga · 9/30/2026
- RBC Capital Reiterates Outperform on Surgery Partners, Maintains $19 Price TargetBenzinga · 9/30/2026
- Surgery Partners, 10x Genomics, QuidelOrtho, Zimmer Biomet, and Tandem Diabetes Stocks Trade Down, What You Need To KnowYahoo · 9/23/2026
- Surgery Partners (SGRY): Buy, Sell, or Hold Post Q2 Earnings?Yahoo · 9/23/2026
- Surgery Partners (SGRY) Soars 15.7%: Is Further Upside Left in the Stock?Yahoo · 9/23/2026
- Surgery Partners: A 'Buy' After Idaho Falls Asset DivestmentSeekingAlpha · 9/23/2026
Insider Activity
Insider Actions →- Teresa DeLuca · August 18, 2026 · Buy10.0K @ $14.35
- Teresa DeLuca · August 18, 2026 · Buy11.3K @ $14.33
- Blair E. Hendrix · June 18, 2026 · Grant34.4K @ $14.55
- John A. Deane · June 5, 2026 · Grant11.7K @ $13.71
- Teresa DeLuca · June 5, 2026 · Grant11.7K @ $13.71
- Laura L. Forese · June 5, 2026 · Grant11.7K @ $13.71
- Lloyd H. Dean · June 5, 2026 · Grant11.7K @ $13.71
- Clifford G. Adlerz · June 5, 2026 · Grant11.7K @ $13.71
- Blair E. Hendrix · June 5, 2026 · Grant11.7K @ $13.71
- Brent Turner · June 5, 2026 · Grant11.7K @ $13.71
Institutional Ownership
March 31, 2026
- Total shares held
- 157.45M
- Total value held
- $1.85B
- Institutional holders
- 176
- Unknown49.95M
- Unknown13.54M
- Unknown12.65M
- Unknown10.23M
- Unknown10.19M
- Unknown5.66M
- Unknown5.30M
- Unknown4.12M
- Unknown3.43M
- Unknown3.34M
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 12, 2026
SGRY Volumes Soften as Analysts Debate Valuation
Surgery Partners is experiencing lower trading volumes while analysts continue to debate its value. Recent reports note a significant five-year decline, yet some estimates suggest the stock is still below fair value. The company remains a point of interest within the Russell 2000, with mixed views on its competitive position and future challenges.
SGRY Volumes Soften as Analysts Debate Valuation. Surgery Partners is experiencing lower trading volumes while analysts continue to debate its value. Recent reports note a significant five-year decline, yet some estimates suggest the stock is still below fair value. The company remains a point of interest within the Russell 2000, with mixed views on its competitive position and future challenges.